Migraine drug could halve the length of attacks, study shows

Researchers say erenumab is ‘incredibly important step forward’ for condition that affects 8.5 million people in UKA new migraine drug that can halve the length of attacks has been hailed as “the start of real change” in how the condition is treated.Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Drugs Health Pharmaceuticals industry UK news World news Biology Science Society Business Source Type: news